Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
plasmaMATCH: ctDNA-directed Targeted Therapies in Advanced Breast Cancer
NCT03182634Phase 2Unknown
- Sponsor
- The Institute of Cancer Research
- Start
- Dec 2016
- Primary completion
- Nov 2022
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of fulvestrant, neratinib, capivasertib, olaparib, ceralasertib in breast cancer, sponsored by The Institute of Cancer Research. Status: unknown.
02
Drugs
fulvestrantneratinibcapivasertibolaparibceralasertib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03182634.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03182634.